{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:25:13Z","timestamp":1740108313376,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Jiangsu Wanbang Biopharmaceuticals Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate the potential ethnic differences of ferric pyrophosphate citrate (FPC, Triferic) in healthy subjects and patients with hemodialysis-dependent stage 5 chronic kidney disease (CKD-5HD) and identify covariates that may influence pharmacokinetics (PK) of FPC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data were collected from 2 Asian and 4 non-Asian clinical studies involving healthy subjects and CKD-5HD patients. Three population PK models were developed: M1 for intravenous (IV) administration of FPC in healthy subjects; M2 for dialysate administration of FPC in CKD-5HD patients; M3 for pre-dialyzer administration of FPC in CKD-5HD\u00a0patients. All the models were fitted to concentration versus time data of FPC using the nonlinear mixed effect approach with the NONMEM<jats:sup>\u00ae<\/jats:sup> program. All statistical analyses were performed using SAS version 9.4.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 26 Asians and 65 non-Asians were included in the final model analysis database. Forty healthy subjects were administered FPC via intravenous (IV) route and 51 patients with CKD-5HD via dialysate (<jats:italic>N<\/jats:italic>\u2009=\u200950) and pre-dialyzer blood circuit administration (<jats:italic>N<\/jats:italic>\u2009=\u200951). The PK parameters of FPC IV were similar. The population PK model showed good parameter precision and reliability as shown by model evaluation, and no relevant influence of ethnicity on PK parameters was observed. In healthy subjects, the maximum observed plasma concentration (C<jats:sub>max<\/jats:sub>) and area under the plasma concentration\u2013time curve (AUC) decreased with increase in lean body mass (LBM) and the average serum total iron at 6\u00a0h before the baseline period (Fe<jats:sub>av<\/jats:sub>), whereas, in both patient populations, C<jats:sub>max<\/jats:sub> and AUC decreased with increase in LBM and decrease in Fe<jats:sub>baseline<\/jats:sub>. Other factors such as gender, age, Fe<jats:sub>av<\/jats:sub>, and ethnicity had no influence on PK exposures in patients. The influence of LBM on PK exposures in patients was smaller than that in healthy subjects (ratio of AUC<jats:sub>0-24<\/jats:sub> for the 5th [68\u00a0kg] and 95th [45\u00a0kg] patient\u2019s LBM was almost 1). The influence of Fe<jats:sub>av<\/jats:sub> and LBM on PK exposures was\u2009&lt;\u200950%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The population pharmacokinetics model successfully described the PK parameters of FPC in healthy subjects and CKD-5HD patients and were comparable between Asian and non-Asian populations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-022-03328-9","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T02:02:32Z","timestamp":1655431352000},"page":"1421-1434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis"],"prefix":"10.1007","volume":"78","author":[{"given":"Lingxiao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangying","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kexin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panpan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongchun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Min","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6235-8137","authenticated-orcid":false,"given":"Qingshan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"issue":"10","key":"3328_CR1","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","volume":"23","author":"JL Babitt","year":"2012","unstructured":"Babitt JL, Lin HY (2012) Mechanisms of anemia in CKD. J Am Soc Nephrol 23(10):1631\u20131634. https:\/\/doi.org\/10.1681\/ASN.2011111078","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3328_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000074931","volume":"22","author":"JA Sargent","year":"2004","unstructured":"Sargent JA, Acchiardo SR (2004) Iron requirements in hemodialysis. Blood Purif 22(1):112\u2013123. https:\/\/doi.org\/10.1159\/000074931","journal-title":"Blood Purif"},{"issue":"23","key":"3328_CR3","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1182\/blood-2010-05-286260","volume":"116","author":"LT Goodnough","year":"2010","unstructured":"Goodnough LT, Nemeth E, Ganz T (2010) Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 116(23):4754\u20134761. https:\/\/doi.org\/10.1182\/blood-2010-05-286260","journal-title":"Blood"},{"issue":"1","key":"3328_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000496492","volume":"142","author":"A Gafter-Gvili","year":"2019","unstructured":"Gafter-Gvili A, Schechter A, Rozen-Zvi B (2019) Iron deficiency anemia in chronic kidney disease. Acta Haematol 142(1):44\u201350. https:\/\/doi.org\/10.1159\/000496492","journal-title":"Acta Haematol"},{"issue":"1","key":"3328_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/sdi.12552","volume":"30","author":"JB Wish","year":"2017","unstructured":"Wish JB (2017) What are the considerations in balancing benefits and risks in iron treatment?: the benefits of intravenous iron. Semin Dial 30(1):20\u201322. https:\/\/doi.org\/10.1111\/sdi.12552","journal-title":"Semin Dial"},{"issue":"4","key":"3328_CR6","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1152\/physrev.00008.2013","volume":"93","author":"T Ganz","year":"2013","unstructured":"Ganz T (2013) Systemic iron homeostasis. Physiol Rev 93(4):1721\u20131741. https:\/\/doi.org\/10.1152\/physrev.00008.2013","journal-title":"Physiol Rev"},{"key":"3328_CR7","doi-asserted-by":"publisher","unstructured":"Locatelli F, Aljama P, B\u00e1r\u00e1ny P et al (2004) Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant\u00a019(Suppl 2):ii1\u201347. https:\/\/doi.org\/10.1093\/ndt\/gfh1032","DOI":"10.1093\/ndt\/gfh1032"},{"key":"3328_CR8","unstructured":"NKF-K\/DOQI clinical practice guidelines for anemia of chronic kidney disease (2001) New York: National Kidney Foundation. Published online\u00a035\u201349"},{"issue":"1","key":"3328_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1053\/j.jrn.2007.10.009","volume":"18","author":"L Garneata","year":"2008","unstructured":"Garneata L (2008) Intravenous iron, inflammation, and oxidative stress: is iron a friend or an enemy of uremic patients? J Ren Nutr 18(1):40\u201345. https:\/\/doi.org\/10.1053\/j.jrn.2007.10.009","journal-title":"J Ren Nutr"},{"issue":"9","key":"3328_CR10","doi-asserted-by":"publisher","first-page":"442","DOI":"10.52586\/4958","volume":"26","author":"S Bhandari","year":"2021","unstructured":"Bhandari S (2021) Impact of intravenous iron on cardiac and skeletal oxidative stress and cardiac mitochondrial function in experimental uraemia chronic kidney disease. Front Biosci (Landmark Ed) 26(9):442\u2013464. https:\/\/doi.org\/10.52586\/4958","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"10","key":"3328_CR11","doi-asserted-by":"publisher","first-page":"E498","DOI":"10.3390\/antiox8100498","volume":"8","author":"F Nuhu","year":"2019","unstructured":"Nuhu F, Seymour AM, Bhandari S (2019) Impact of intravenous iron on oxidative stress and mitochondrial function in experimental chronic kidney disease. Antioxidants (Basel) 8(10):E498. https:\/\/doi.org\/10.3390\/antiox8100498","journal-title":"Antioxidants (Basel)"},{"issue":"3","key":"3328_CR12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jcph.819","volume":"57","author":"RD Pratt","year":"2017","unstructured":"Pratt RD, Swinkels DW, Ikizler TA, Gupta A (2017) Pharmacokinetics of ferric pyrophosphate citrate, a novel iron salt, administered intravenously to healthy volunteers. J Clin Pharmacol 57(3):312\u2013320. https:\/\/doi.org\/10.1002\/jcph.819","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"3328_CR13","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s10534-018-0142-2","volume":"31","author":"R Pratt","year":"2018","unstructured":"Pratt R, Handelman GJ, Edwards TE, Gupta A (2018) Ferric pyrophosphate citrate: interactions with transferrin. Biometals 31(6):1081\u20131089. https:\/\/doi.org\/10.1007\/s10534-018-0142-2","journal-title":"Biometals"},{"key":"3328_CR14","unstructured":"206317s000lbl.pdf. Accessed August 30, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206317s000lbl.pdf"},{"key":"3328_CR15","doi-asserted-by":"publisher","unstructured":"Marbury T, van Heuveln F, van der Horst E, Pratt RD (2021) Pharmacokinetics and safety of intravenous ferric pyrophosphate citrate: equivalence to administration via dialysate. J Clin Pharmacol. Published online November 7, 2021. https:\/\/doi.org\/10.1002\/jcph.1997","DOI":"10.1002\/jcph.1997"},{"issue":"5","key":"3328_CR16","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1046\/j.1523-1755.1999.00436.x","volume":"55","author":"A Gupta","year":"1999","unstructured":"Gupta A, Amin NB, Besarab A et al (1999) Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int 55(5):1891\u20131898. https:\/\/doi.org\/10.1046\/j.1523-1755.1999.00436.x","journal-title":"Kidney Int"},{"issue":"5","key":"3328_CR17","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1067\/mlc.2000.110368","volume":"136","author":"A Gupta","year":"2000","unstructured":"Gupta A, Crumbliss AL (2000) Treatment of iron deficiency anemia: are monomeric iron compounds suitable for parenteral administration? J Lab Clin Med 136(5):371\u2013378. https:\/\/doi.org\/10.1067\/mlc.2000.110368","journal-title":"J Lab Clin Med"},{"issue":"5","key":"3328_CR18","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ki.2015.203","volume":"88","author":"A Gupta","year":"2015","unstructured":"Gupta A, Lin V, Guss C, Pratt R, Ikizler TA, Besarab A (2015) Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney Int 88(5):1187\u20131194. https:\/\/doi.org\/10.1038\/ki.2015.203","journal-title":"Kidney Int"},{"issue":"12","key":"3328_CR19","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1093\/ndt\/gfv277","volume":"30","author":"SN Fishbane","year":"2015","unstructured":"Fishbane SN, Singh AK, Cournoyer SH et al (2015) Ferric pyrophosphate citrate (Triferic\u2122) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Nephrol Dial Transplant 30(12):2019\u20132026. https:\/\/doi.org\/10.1093\/ndt\/gfv277","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"3328_CR20","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1007\/s00467-018-4014-3","volume":"33","author":"RD Pratt","year":"2018","unstructured":"Pratt RD, Grimberg S, Zaritsky JJ, Warady BA (2018) Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis. Pediatr Nephrol 33(11):2151\u20132159. https:\/\/doi.org\/10.1007\/s00467-018-4014-3","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"3328_CR21","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2165\/00003088-200645100-00001","volume":"45","author":"ML Chen","year":"2006","unstructured":"Chen ML (2006) Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 45(10):957\u2013964. https:\/\/doi.org\/10.2165\/00003088-200645100-00001","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3328_CR22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/2160763X12455329","volume":"1","author":"Y Sugita","year":"2012","unstructured":"Sugita Y, Inoue E, Narukawa M (2012) Impact of clinical response on different approved doses in japan and the United States. Clin Pharmacol Drug Dev 1(4):158\u2013169. https:\/\/doi.org\/10.1177\/2160763X12455329","journal-title":"Clin Pharmacol Drug Dev"},{"key":"3328_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.24","volume":"2","author":"RJ Keizer","year":"2013","unstructured":"Keizer RJ, Karlsson MO, Hooker A (2013) Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol 2:e50. https:\/\/doi.org\/10.1038\/psp.2013.24","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"3328_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4","volume":"1","author":"DR Mould","year":"2012","unstructured":"Mould DR, Upton RN (2012) Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol 1:e6. https:\/\/doi.org\/10.1038\/psp.2012.4","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"3328_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN (2013) Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 2:e38. https:\/\/doi.org\/10.1038\/psp.2013.14","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"3328_CR26","unstructured":"Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs \u2014 General Considerations (2014) Published online 29"},{"issue":"1","key":"3328_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/bcp.12352","volume":"79","author":"J Nyberg","year":"2015","unstructured":"Nyberg J, Bazzoli C, Ogungbenro K et al (2015) Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies. Br J Clin Pharmacol 79(1):6\u201317. https:\/\/doi.org\/10.1111\/bcp.12352","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"3328_CR28","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1021\/js9702168","volume":"86","author":"JA Johnson","year":"1997","unstructured":"Johnson JA (1997) Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci 86(12):1328\u20131333. https:\/\/doi.org\/10.1021\/js9702168","journal-title":"J Pharm Sci"},{"issue":"2","key":"3328_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.blre.2013.12.003","volume":"28","author":"WG Murphy","year":"2014","unstructured":"Murphy WG (2014) The sex difference in haemoglobin levels in adults - mechanisms, causes, and consequences. Blood Rev 28(2):41\u201347. https:\/\/doi.org\/10.1016\/j.blre.2013.12.003","journal-title":"Blood Rev"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03328-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03328-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03328-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T07:06:13Z","timestamp":1660115173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03328-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["3328"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03328-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"7 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Y. T., G. W., and A. H. are employees of Shanghai Fosun Pharmaceutical Development, Co., Ltd, Shanghai, China. X. Y. and Y. Z. are employees of Jiangsu Wanbang Biopharmaceuticals Co., Ltd., Jiangsu, China. R. P. is a full-time employee of Rockwell Medical Inc., USA, and received salary and stock options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}